what is glp 1 receptor agonist Science Behind GIP and Glucagon Agonists for Obesity Research | News & Announcements Study finds GLP-1 receptor agonists

Based on the route of administration, the GLP-1 receptor agonist market is classified into parenteral and oral segments

[DOI] [PMC free article] [PubMed] [Google Scholar] 202.Bloomer R., et al

Food and Drug Administration approved its oral glucagonlike peptide 1 (GLP-1) medication for weight loss and obesity in adults

Key findings at the highest dose (12mg weekly): Up to 24% mean body weight reduction over 48 weeks Significant reductions in fasting glucose and insulin resistance markers Meaningful reductions in liver fat content, relevant for participants with metabolic-associated fatty liver disease Once-weekly subcutaneous dosing was generally well-tolerated For context, semaglutide at its approved dose achieves approximately 1517% body weight reduction over 68 weeks

[DOI] [PubMed] [Google Scholar] 58.Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., et al

2020;5:e133429